Objective: EVA1B, a protein coding gene, is a critical paralog of EVA1A gene. Herein, our study was conducted to investigate the role of EVA1B in colorectal cancer (CRC) progression and prognosis.
Methods: Pan-cancer analysis was conducted to analyze expression, genetic and epigenetic alterations, and immunological characteristics of EVA1B. Especially, immunological characteristics and mutational landscape were compared between high and low EVA1B expression groups in the combined TCGA-COAD and TCGA-READ datasets. Through random survival forest analysis, an EVA1B-derived genomic model was developed, and its prognostic value was verified in the external datasets (GSE14333, GSE39582, and GSE87211). Drug sensitivity was compared between high- and low-risk subpopulations. A nomogram was conducted through integrating independent factors.
Results: EVA1B expression presented a remarkable upregulation in most cancer types, especially CRC. EVA1B expression was significantly correlated to DNA methyltransferases, DNA mismatch repair genes, mA regulators, TMB, and MSI across pan-cancer. High EVA1B expression indicated an undesirable CRC patients' prognosis. Additionally, its upregulation was correlated to enhanced immune cell infiltration, increased stromal and immune activation, and elevated activities of cancer immunity cycle. Higher frequencies of amplification and deletion were investigated in high EVA1B expression subpopulation. Following verification, the EVA1B-derived genomic model reliably predicted patients' prognosis and drug responses. The nomogram (age, stage, EVA1B-derived risk score) was conducted to quantify an individual's survival probability. Furthermore, our experimental validation based on immunohistochemistry indicated that EVA1B overexpression is correlated with CRC tumorigenesis and poor outcomes in our CRC patients' cohort.
Conclusion: Collectively, our findings provided valuable resource for guiding the mechanisms and therapeutic analysis of EVA1B in CRC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888821 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.809837 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment.
Pharmacol Res
December 2024
Department of Thoracic Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan 450003, China. Electronic address:
Article Synopsis
- EVA1B is found to be significantly up-regulated in esophageal squamous cell carcinoma (ESCC) tissues, linking it to advanced cancer stages and increased myeloid-derived suppressor cells (MDSCs).
- Silencing EVA1B leads to reduced proliferation and tumor growth in ESCC cells and mouse models, promoting apoptosis and disrupting cell cycle progression.
- The study suggests that targeting EVA1B could hinder both ESCC progression and MDSC activity, highlighting its potential as a therapeutic strategy for ESCC patients.
Construction and Validation of a Prognostic Model Based on mRNAsi-Related Genes in Breast Cancer.
Comput Math Methods Med
October 2022
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China.
Article Synopsis
- Breast cancer poses a significant threat to women globally, leading to considerable health issues and deaths, prompting the need for a genetic model to predict survival rates based on mRNAsi.
- The study utilized data from TCGA and GEO to analyze gene expressions, employing machine learning and various statistical methods to explore the relationship between mRNAsi and clinical data, including immune responses and gene coexpression.
- The findings identified nine key genes associated with mRNAsi that form a prognostic model, demonstrating the potential to improve survival predictions and further understand breast cancer biology.
Molecular Characteristics, Oncogenic Roles, and Relevant Immune and Pharmacogenomic Features of EVA1B in Colorectal Cancer.
Front Immunol
May 2022
Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Objective: EVA1B, a protein coding gene, is a critical paralog of EVA1A gene. Herein, our study was conducted to investigate the role of EVA1B in colorectal cancer (CRC) progression and prognosis.
Methods: Pan-cancer analysis was conducted to analyze expression, genetic and epigenetic alterations, and immunological characteristics of EVA1B.
to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma.
Front Immunol
October 2021
Department of Clinical Pharmacy, Lishui People's Hospital (The Sixth Affiliated Hospital of Wenzhou Medical University), Lishui, China.
Background: Previous research indicated that the tumor cells and microenvironment interactions are critical for the immunotherapeutic response. However, predicting the clinical response to immunotherapy remains a dilemma for clinicians. Hence, this study aimed to investigate the associations between expression and prognosis and tumor-infiltrating immune cells in glioma.
View Article and Find Full Text PDFIdentification of DNA-Methylated CpG Islands Associated With Gene Silencing in the Adult Body Tissues of the Ogye Chicken Using RNA-Seq and Reduced Representation Bisulfite Sequencing.
Front Genet
April 2019
Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
DNA methylation is an epigenetic mark that plays an essential role in regulating gene expression. CpG islands are DNA methylations regions in promoters known to regulate gene expression through transcriptional silencing of the corresponding gene. DNA methylation at CpG islands is crucial for gene expression and tissue-specific processes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!